A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Briakinumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 08 Mar 2016 Pooled analysis (n=1692) of 4 trials (NCT00237887, NCT00235820, NCT00691964, NCT00710580) were presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 08 Feb 2011 Results presented at the 69th Annual Meeting of the American Academy of Dermatology.
    • 08 Feb 2011 Pooled efficacy and tolerability analysis presented at the 69th Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top